American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 421-432 , September 2007

Should Hemodialysis Patients With Atrial Fibrillation Undergo Systemic Anticoagulation? A Cost-Utility Analysis

  • Robert R. Quinn, MD, FRCPC

      Affiliations

    • Department of Medicine, Division of Nephrology, Sunnybrook Health Sciences Centre, Toronto, Canada
    • Corresponding Author InformationAddress correspondence to Robert R. Quinn, MD, FRCPC, Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, 2075 Bayview Ave, Rm A239, Toronto, Ontario, Canada M4N 3M5.
    • ,
  • David M.J. Naimark, MD, MSc, FRCPC

      Affiliations

    • Department of Medicine, Division of Nephrology, Sunnybrook Health Sciences Centre, Toronto, Canada
    • Medicine and Health Policy Management and Evaluation, University of Toronto, Toronto, Canada
    • ,
  • Matthew J. Oliver, MD, MHS, FRCPC

      Affiliations

    • Chronic Dialysis, Sunnybrook Health Sciences Centre, Toronto, Canada
    • ,
  • Ahmed M. Bayoumi, MD, MSc, FRCPC

      Affiliations

    • Medicine and Health Policy Management and Evaluation, University of Toronto, Toronto, Canada
    • Centre for Research on Inner City Health, The Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael’s Hospital, University of Toronto, Toronto, Canada.

Received 19 December 2006 ,Accepted 23 May 2007.

References 

  1. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(suppl 3):S429–S456
  2. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: Full text: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006;8:651–745
  3. Vazquez E, Sanchez-Perales C, Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. Am Heart J. 2000;140:886–890
  4. Vazquez E, Sanchez-Perales C, Lozano C, et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol. 2003;92:868–871
  5. Biggers JA, Remmers AR, Glassford DM, Sarles HE, Lindley JD, Fish JC. The risk of anticoagulation in hemodialysis patients. Nephron. 1977;18:109–113
  6. Vazquez E, Sanchez-Perales C, Garcia-Cortes MJ, et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?. Int J Cardiol. 2003;87:135–139
  7. Abbott KC, Trespalacios FC, Taylor AJ, Agodoa LY. Atrial fibrillation in chronic dialysis patients in the United States: Risk factors for hospitalization and mortality. BMC Nephrol. 2003;4:1
  8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation (Analysis of pooled data from five randomized controlled trials). Arch Intern Med. 1994;154:1449–1457
  9. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med. 1999;131:492–501
  10. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996;50:235–242
  11. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829–1836
  12. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: A systematic review of the literature. Stroke. 2001;32:1425–1429
  13. Bruns FJ, Seddon P, Saul M, Zeidel ML. The cost of caring for end-stage kidney disease patients: An analysis based on hospital financial transaction records. J Am Soc Nephrol. 1998;9:884–890
  14. Menzin J, Boulanger L, Hauch O, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: A multi-site managed-care study. Ann Pharmacother. 2005;39:446–451
  15. Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: Clopidogrel plus aspirin versus aspirin alone. Ann Intern Med. 2005;142:251–259
  16. Agency for Health Care Policy and Research: Healthcare Cost and Utilization Project (HCUP). 1995 HCUP-3 nationwide inpatient sample (NIS), 2005. Available at: www.ahcpr.gov/data/hcup/his95/clinclas.htm#healthca. Accessed July 25, 2005
  17. Department of Health and Human Services: Changes to the hospital inpatient prospective payment systems and fiscal year 2005 rates. Available at: www.cms.hhs.gov/providers/hipps/frnotices.asp. Accessed July 25, 2005
  18. Centers for Medicare & Medicaid Services: CMS files for download for Medicare payment systems. 2005 physician fee schedule payment amount file national/carrier. Available at: www.cms.hhs.gov/providers/pufdownload/default.asp#utilmisc. Accessed July 25, 2005
  19. US Department of Labor. Bureau of Labor Statistics: Consumer price indexes. Available at: www.bls.gov/cpi/#data. Accessed July 25, 2005
  20. Gold MR. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996;
  21. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med. 1998;13:716–717
  22. Briggs AH, Goeree R, Blackhouse G, O’Brien BJ. Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making. 2002;22:290–308
  23. Manns B, Meltzer D, Taub K, Donaldson C. Illustrating the impact of including future costs in economic evaluations: An application to end-stage renal disease care. Health Econ. 2003;12:949–958
  24. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions—Standardizing data on outcomes. N Engl J Med. 1998;339:380–386
  25. Wiesholzer M, Harm F, Tomasec G, Barbieri G, Putz D, Balcke P. Incidence of stroke among chronic hemodialysis patients with nonrheumatic atrial fibrillation. Am J Nephrol. 2001;21:35–39
  26. Schori TR, Stungis GE. Long-term warfarin treatment may induce arterial calcification in humans: Case report. Clin Invest Med. 2004;27:107–109
  27. Goodkin DA, Young EW, Kurokawa K, Prutz KG, Levin NW. Mortality among hemodialysis patients in Europe, Japan, and the United States: Case-mix effects. Am J Kidney Dis. 2004;44(suppl 3):S16–S21
  28. Rodriguez-Carmona A, Perez FM, Bouza P, Garcia FT, Valdes F. The economic cost of dialysis: A comparison between peritoneal dialysis and in-center hemodialysis in a Spanish unit. Adv Perit Dial. 1996;12:93–96
  29. Croxson BE, Ashton T. A cost effectiveness analysis of the treatment of end stage renal failure. N Z Med J. 1990;103:171–174
  30. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy. 1998;44:215–232
  31. Goeree R, Manalich J, Grootendorst P, Beecroft ML, Churchill DN. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med. 1995;18:455–464
  32. Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002;40:611–622
  33. US Renal Data System: 2006 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;
  34. Manns BJ, Johnson JA, Taub K, Mortis G, Ghali WA, Donaldson C. Quality of life in patients treated with hemodialysis or peritoneal dialysis: What are the important determinants?. Clin Nephrol. 2003;60:341–351
  35. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839–1845
  36. Iseki K, Fukiyama K The Okinawa Dialysis Study (OKIDS) Group. Clinical demographics and long-term prognosis after stroke in patients on chronic haemodialysis. Nephrol Dial Transplant. 2000;15:1808–1813
  37. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019–1026
  38. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164:880–884
  39. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology. 2001;56:773–777
  40. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897–902

 Originally published online as doi:10.1053/j.ajkd.2007.05.019 on August 9, 2007.

PII: S0272-6386(07)00844-X

doi: 10.1053/j.ajkd.2007.05.019

American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 421-432 , September 2007

Article Tools

* Image Usage & Resolution